Clinical Trials · NCT02113553
Anti-Mullerian Hormone (AMH) as Marker of Ovarian Reserve
- Phase
- Phase 2
- Recruitment status
- Terminated
- Sponsor
- Armando Santoro, MD
- Enrollment
- 45
- Start date
- May 2013
- Locations
- 1 site, Italy
- Primary endpoint
- AMH in response to chemotherapy plus GnRHa